Residency · Residency · Psychiatry

Opioid Use Disorder: Medication-Assisted Treatment

Epidemiology and Context

~2.7 million Americans with OUD; ~100,000 opioid overdose deaths/year in the US (2022-2023) Fentanyl has overtaken heroin and prescription opioids as the leading cause of overdose death. OUD has the highest mortality of any substance use disorder. Only ~20% of individuals with OUD receive medication treatment. Terminology note: "medication-assisted treatment (MAT)" is being replaced by "medications for opioid use disorder (MOUD)" to emphasize that medication IS treatment, not merely an adjunct.

Neurobiology

Mu-opioid receptor (MOR) activation produces analgesia, euphoria, respiratory depression, and miosis. Chronic opioid exposure leads to receptor desensitization and downregulation, neuroadaptation in the locus coeruleus (noradrenergic hyperactivity in withdrawal), and mesolimbic dopamine circuit changes. Withdrawal: opposite of intoxication -- noradrenergic storm (lacrimation, rhinorrhea, piloerection, diarrhea, mydriasis, tachycardia, hypertension, anxiety, insomnia) While profoundly uncomfortable, opioid withdrawal is rarely life-threatening (unlike alcohol or benzodiazepine withdrawal) -- exception: dehydration in severe cases, and risk in neonates.

Medications for Opioid Use Disorder

Buprenorphine

Pharmacology

Partial mu-opioid agonist and kappa antagonist. Ceiling effect on respiratory depression (safer in overdose than full agonists) High receptor binding affinity -- can displace full agonists, precipitating withdrawal if given too early. Long half-life (~24-60 hours); suitable for once-daily dosing.

Formulations

Sublingual/buccal: buprenorphine/naloxone (Suboxone); naloxone component deters IV misuse (naloxone is poorly absorbed sublingually but active if injected) Buprenorphine monoproduct (Subutex): used in pregnancy (avoids fetal naloxone exposure, though recent evidence suggests combination product may also be safe) Subdermal implant (Probuphine): 6-month implant for stable patients on <= 8 mg/day. Monthly injection (Sublocade): subcutaneous depot injection; eliminates adherence concerns.

Induction

Standard induction: wait for moderate withdrawal (COWS score >= 12) before first dose to avoid precipitated withdrawal; start 2-8 mg, titrate over days to effective dose (typically 16 mg/day, max 24 mg) Micro-dosing / Bernese method: very low initial doses (0.5 mg) given while patient continues full agonist use, gradually increasing buprenorphine while tapering the full agonist; avoids withdrawal entirely; particularly useful with fentanyl (which has unpredictable precipitated withdrawal timing) Fentanyl challenge: fentanyl's lipophilicity and tissue accumulation mean patients may need to wait 72+ hours for traditional induction -- micro-dosing is increasingly preferred.

Prescribing

X-waiver requirement eliminated in 2023 (MATE Act) -- any DEA-licensed prescriber can prescribe buprenorphine for OUD. 8-hour MATE training requirement for new DEA registrants. Can be prescribed in office-based settings (unlike methadone for OUD)

Methadone

Pharmacology

Full mu-opioid agonist; also NMDA receptor antagonist. Long half-life (24-36 hours; up to 60 hours with chronic dosing) No ceiling effect on respiratory depression -- overdose risk is real, especially during induction. QTc prolongation risk (monitor ECG)

Administration

In the US, methadone for OUD can ONLY be dispensed through federally regulated Opioid Treatment Programs (OTPs) Daily observed dosing initially; take-home privileges earned with treatment stability. Starting dose: 20-30 mg/day; increase by 5-10 mg every 5-7 days; therapeutic range typically 60-120 mg/day. Deaths during induction are most common in the first 2 weeks (accumulation before steady state)

Evidence

Strongest evidence base of any OUD treatment: reduces illicit opioid use, overdose mortality (~50% reduction), HIV transmission, criminal activity. Retains patients in treatment better than buprenorphine and much better than naltrexone. Limitations: diversion risk, QTc prolongation, drug interactions, stigma of daily clinic visits.

Extended-Release Naltrexone (Vivitrol)

Pharmacology

Full mu-opioid antagonist; blocks opioid effects for ~30 days per injection. No agonist activity, no abuse potential, no diversion risk. Requires full opioid detoxification before initiation (7-10 days opioid-free for short-acting, 10-14 days for methadone) -- this is the major barrier.

Evidence

X:BOT trial (2018): naltrexone vs. buprenorphine; intention-to-treat analysis favored buprenorphine (more patients successfully initiated treatment); among those who started medication, relapse rates were similar. Lower retention in treatment compared to agonist therapies. Best candidates: highly motivated patients, patients in criminal justice settings, patients who prefer non-agonist treatment, healthcare professionals.

Comparison of Medications

Harm Reduction

Naloxone Distribution

Opioid antagonist; rapidly reverses opioid overdose. Available OTC (Narcan nasal spray) since 2023. All patients with OUD and their close contacts should be provided naloxone. Fentanyl overdoses may require multiple doses due to high potency.

Other Harm Reduction Strategies

Syringe services programs (reduce HIV and HCV transmission) Fentanyl test strips. Supervised consumption sites (evidence supports reduction in overdose deaths; legal status varies) Drug checking services.

The Controversy: Abstinence-Based vs. Medication-First Approaches

Historically, many 12-step programs and residential facilities rejected MOUD as "replacing one drug with another". Evidence clearly supports MOUD as the standard of care: reduces overdose deaths by 50%+, improves retention, reduces HIV/HCV, improves social functioning. Abstinence-only approaches have higher relapse and mortality rates. Current consensus: MOUD is evidence-based treatment, not "substitution"; indefinite maintenance is appropriate for many patients. Tapering off MOUD should be patient-driven, gradual, and undertaken only when the patient is stable and desires it -- relapse rates are high after discontinuation.

<image> A comparison diagram of the three FDA-approved medications for opioid use disorder. Three columns for buprenorphine, methadone, and extended-release naltrexone. For each: mechanism of action at the mu-opioid receptor (partial agonist, full agonist, antagonist), receptor occupancy and effect diagram, prescribing setting, induction requirements, advantages, disadvantages, retention rates, and mortality reduction data. Include a visual representation of receptor pharmacology (partial vs. full agonist vs. antagonist). Clinical education format. </image>

<image> A step-by-step diagram of buprenorphine induction comparing standard induction vs. micro-dosing (Bernese method). Standard induction: wait for COWS >= 12, then start 2-4 mg SL, observe, redose to 8 mg on day 1, titrate to 16 mg by day 2-3. Micro-dosing: start 0.5 mg while patient continues full agonist, gradually increase buprenorphine (day 1: 0.5 mg, day 2: 0.5 mg BID, day 3: 1 mg BID, etc.) while tapering full agonist, complete transition by day 7-10. Highlight why micro-dosing is preferred with fentanyl. Timeline format. </image>

<image> A flowchart for OUD treatment selection. Start with "OUD diagnosed." First: ensure naloxone provided to patient and contacts. Then: assess patient preferences, treatment setting, comorbidities. Branch to buprenorphine (office-based, moderate-severe OUD, can tolerate mild withdrawal or use micro-dosing), methadone (severe OUD, failed buprenorphine, high tolerance, prefers structured setting), or XR-naltrexone (completed detox, prefers antagonist, criminal justice, healthcare professionals). Include ongoing monitoring and adjustment pathway. Color-coded algorithm. </image>

Clinical Pearls

Buprenorphine micro-dosing (Bernese method) is increasingly the preferred induction strategy in the fentanyl era -- it avoids the unpredictable precipitated withdrawal seen with traditional induction from fentanyl. The X-waiver is gone -- any DEA-licensed prescriber can now prescribe buprenorphine for OUD; the main remaining barrier is clinician willingness. Methadone for OUD can only be dispensed through OTPs (methadone for pain can be prescribed by any provider -- an important regulatory distinction) Extended-release naltrexone works well for motivated patients, but the requirement for 7-14 days of opioid abstinence before initiation is a major practical barrier -- many patients relapse during this window. MOUD reduces all-cause mortality by ~50%; withholding it is not a neutral decision. Prescribe naloxone to every patient with OUD and educate their household contacts on its use. Opioid withdrawal is not life-threatening in adults, but it is profoundly uncomfortable and drives continued use; managing withdrawal is important but is NOT equivalent to treating OUD -- maintenance MOUD is the standard of care.

References

• Wakeman SE, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.
• Lee JD, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT). Lancet. 2018;391(10118):309-318.
• Hakkinen M, et al. Micro-dosing buprenorphine induction: a systematic review. J Addict Med. 2022;16(5):e312-e319.
• SAMHSA. Medications for Opioid Use Disorder: TIP 63. 2021.
• Mattick RP, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209.

Read this lecture as Markdown